Literature DB >> 20737298

The use of cell-delivered gene therapy for the treatment of HIV/AIDS.

Geoff P Symonds1, Helen A Johnstone, Michelle L Millington, Maureen P Boyd, Bryan P Burke, Louis R Breton.   

Abstract

HIV/AIDS is a disease that impairs immune function, primarily by decreasing T-lymphocyte count. Its progression can be contained by highly active antiretroviral therapy (HAART), but there are side effects that can be severe, and the development of resistance often forces the physician to modify the HAART regimen. There are no vaccines available for HIV. An alternative approach that could provide a path to a curative therapy is the use of cell-delivered gene therapy in which an anti-HIV gene(s) is introduced into hematopoietic cells to produce a population that is protected from the effects of HIV. In this paper, we review the field and discuss an approach using a short hairpin RNA to CCR5, an important co-receptor for HIV.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20737298     DOI: 10.1007/s12026-010-8169-7

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  73 in total

1.  Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo.

Authors:  J Bai; S Gorantla; N Banda; L Cagnon; J Rossi; R Akkina
Journal:  Mol Ther       Date:  2000-03       Impact factor: 11.454

2.  Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance.

Authors:  Joseph Anderson; Akhil Banerjea; Ramesh Akkina
Journal:  Oligonucleotides       Date:  2003

3.  Gene therapy fulfilling its promise.

Authors:  Donald B Kohn; Fabio Candotti
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

4.  Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals.

Authors:  Richard A Morgan; Robert Walker; Charles S Carter; Ven Natarajan; Jorge A Tavel; Chris Bechtel; Betsy Herpin; Linda Muul; Zhili Zheng; Shyla Jagannatha; Bruce A Bunnell; Vicki Fellowes; Julia A Metcalf; Randy Stevens; Michael Baseler; Susan F Leitman; Elizabeth J Read; R Michael Blaese; H Clifford Lane
Journal:  Hum Gene Ther       Date:  2005-09       Impact factor: 5.695

5.  Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Authors:  Mike Westby; Caroline Smith-Burchnell; Julie Mori; Marilyn Lewis; Michael Mosley; Mark Stockdale; Patrick Dorr; Giuseppe Ciaramella; Manos Perros
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

6.  Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus.

Authors:  Jan van Lunzen; Tobias Glaunsinger; Ingrid Stahmer; Volker von Baehr; Christopher Baum; Andrea Schilz; Klaus Kuehlcke; Sonja Naundorf; Holger Martinius; Felix Hermann; Tsanan Giroglou; Sebastian Newrzela; Ingrid Müller; Francis Brauer; Gunda Brandenburg; Alexander Alexandrov; Dorothee von Laer
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

7.  Design of HIV vectors for efficient gene delivery into human hematopoietic cells.

Authors:  Priscilla Y Yam; Shulian Li; Jerry Wu; Jun Hu; John A Zaia; Jiing-Kuan Yee
Journal:  Mol Ther       Date:  2002-04       Impact factor: 11.454

8.  Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes.

Authors:  G Bauer; P Valdez; K Kearns; I Bahner; S F Wen; J A Zaia; D B Kohn
Journal:  Blood       Date:  1997-04-01       Impact factor: 22.113

9.  Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients.

Authors:  Rafael G Amado; Ronald T Mitsuyasu; Joseph D Rosenblatt; Frances K Ngok; Andreas Bakker; Steve Cole; Nathalie Chorn; Lii-Shin Lin; Gregory Bristol; Maureen P Boyd; Janet L MacPherson; Gregory C Fanning; Alison V Todd; Julie A Ely; Jerome A Zack; Geoff P Symonds
Journal:  Hum Gene Ther       Date:  2004-03       Impact factor: 5.695

10.  Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients.

Authors:  C Woffendin; U Ranga; Z Yang; L Xu; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

View more
  11 in total

Review 1.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

Review 2.  Ex vivo gene therapy for HIV-1 treatment.

Authors:  Lisa J Scherer; John J Rossi
Journal:  Hum Mol Genet       Date:  2011-04-19       Impact factor: 6.150

3.  Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt.

Authors:  Ronald T Mitsuyasu; Jerome A Zack; Janet L Macpherson; Geoff P Symonds
Journal:  Stem Cells Int       Date:  2011-06-13       Impact factor: 5.443

4.  Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor.

Authors:  Orit Wolstein; Maureen Boyd; Michelle Millington; Helen Impey; Joshua Boyer; Annett Howe; Frederic Delebecque; Kenneth Cornetta; Michael Rothe; Christopher Baum; Tamara Nicolson; Rachel Koldej; Jane Zhang; Naomi Keech; Joanna Camba Colón; Louis Breton; Jeffrey Bartlett; Dong Sung An; Irvin Sy Chen; Bryan Burke; Geoff P Symonds
Journal:  Mol Ther Methods Clin Dev       Date:  2014-02-12       Impact factor: 6.698

5.  Targeted genome engineering in human induced pluripotent stem cells by penetrating TALENs.

Authors:  Renli Ru; Yongchao Yao; Songlin Yu; Benpeng Yin; Wanwan Xu; Siting Zhao; Li Qin; Xiaoping Chen
Journal:  Cell Regen (Lond)       Date:  2013-06-18

Review 6.  An Update on the HIV DNA Vaccine Strategy.

Authors:  Joseph Hokello; Adhikarimayum Lakhikumar Sharma; Mudit Tyagi
Journal:  Vaccines (Basel)       Date:  2021-06-05

7.  Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice.

Authors:  Gene-Errol E Ringpis; Saki Shimizu; Hubert Arokium; Joanna Camba-Colón; Maria V Carroll; Ruth Cortado; Yiming Xie; Patrick Y Kim; Anna Sahakyan; Emily L Lowe; Munetoshi Narukawa; Fadi N Kandarian; Bryan P Burke; Geoff P Symonds; Dong Sung An; Irvin S Y Chen; Masakazu Kamata
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

8.  Pol III Promoters to Express Small RNAs: Delineation of Transcription Initiation.

Authors:  Hongming Ma; Yonggan Wu; Ying Dang; Jang-Gi Choi; Junli Zhang; Haoquan Wu
Journal:  Mol Ther Nucleic Acids       Date:  2014-05-06       Impact factor: 10.183

9.  A quantitative comparison of anti-HIV gene therapy delivered to hematopoietic stem cells versus CD4+ T cells.

Authors:  Borislav Savkovic; James Nichols; Donald Birkett; Tanya Applegate; Scott Ledger; Geoff Symonds; John M Murray
Journal:  PLoS Comput Biol       Date:  2014-06-19       Impact factor: 4.475

Review 10.  Recent Advances in Lentiviral Vaccines for HIV-1 Infection.

Authors:  Thomas D Norton; Elizabeth A Miller
Journal:  Front Immunol       Date:  2016-06-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.